Clinical Trials
3 trialsNCT02390427 2026-04-09
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04042051 2025-07-22
Panthera
Cancer Trials Ireland
Phase 1 Terminated
NCT05650879 2025-07-15
HER2
Enliven Therapeutics
Phase 1 Active not recruiting